UNSPSC 51151549: Rivastigmine hydrogen tartrate

This classification denotes an acetylcholinesterase inhibitor with the molecular formula C14H22N2O2.C4H6O6, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 9IY2357JPE, chemically known as 2,6-dioxo-4-phenyl-piperidine-3-carbonitrile but more generally known as rivastigmine hydrogen tartrate, which bears US NIH Compound Identifier 77991. European Medicines Agency schedules Rivastigmine hydrogen tartrate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB04257MIG.

Most nations, for tariff and trade purposes, schedule rivastigmine hydrogen tartrate under HS 29242995 and SITC 51479. SMILES: CCN(C)C(=O)OC1CCCC(C1)[C@H](C)N(C)C.[C@@H]([C@H](C(=O)O)O)(C(=O)O)O.

UNSPSC 51151549 Rivastigmine hydrogen tartrate is a Commodity code in the pharmaceutical products taxonomy, but the recent state and local opportunities tagged under it involve procurement of naloxone and drug deactivation systems for community health initiatives, not rivastigmine specifically. The code shows a mismatch between its nominal scope and the work actually being solicited: the Seminole County, Florida IFB released in June 2026 seeks naloxone units and safe drug deactivation systems for quarterly delivery to a county health facility, while the Texas Health and Human Services Commission RFI posted in April 2026 solicits vendor capabilities for a direct-to-manufacturer prescription program involving pharmacy benefit management and negotiated pricing models. Neither opportunity directly targets the cholinesterase inhibitor pharmaceutical named in the code. State and local health departments and human services commissions are the primary issuing bodies tagged under this code in recent activity, though the opportunities themselves diverge substantially from each other in scope and delivery model.

Geographically, the recent activity spans Florida and Texas, though the sample is too limited to characterize broader regional concentration. Seminole County's IFB (Solicitation IFB60459723LAS, due July 26, 2023, though posted June 30, 2026) calls for competitive bidding on 1,900 units of naloxone and 800 deactivation systems annually with quarterly deliveries, fixed-fee pricing, and standard compliance requirements including E-Verify and insurance documentation. The Texas HHS Commission's RFI (HHS0017013, response deadline April 3, 2026) functions as early-stage market research rather than a binding procurement, seeking vendor information about direct contracting with manufacturers, self-insured health plans, and negotiated net-pricing models without traditional pharmacy benefit manager intermediaries. Neither opportunity specifies set-aside designations for disadvantaged enterprises. The code shows little relevant recent activity aligned to its pharmaceutical product name, suggesting either mistagging of opportunities or minimal current demand for rivastigmine hydrogen tartrate through state and local procurement channels.